Implementing reflective multicriteria decision analysis (MCDA) to assess orphan drugs value in the Catalan Health Service (CatSalut) by Guarga Laura et al.
RESEARCH Open Access
Implementing reflective multicriteria
decision analysis (MCDA) to assess orphan
drugs value in the Catalan Health Service
(CatSalut)
Laura Guarga1,2, Xavier Badia2, Mercè Obach1, Manel Fontanet1,3, Alba Prat1, Atonio Vallano1, Josep Torrent1 and
Caridad Pontes1,3*
Abstract
Background: Orphan medicines show some characteristics that hinder the evaluation of their clinical added value.
The often low level of evidence available for orphan drugs, together with a high budget impact and an
incremental cost-effectiveness ratio many times higher than drugs used for non-orphan diseases, represent
challenges in their appraisal and effective access to clinical use. In order to explore how to handle these hurdles,
the Catalan Health Service (CatSalut) began an initiative on a multidimensional assessment of drugs value during
the appraisal process. Reflective multicriteria decision analysis (MCDA) using analytical methods was chosen, since it
may help to standardise and contextualize all the relevant data related with the drug that could contribute to a
decision. The aim of the study was to determine whether the implementation of reflective MCDA methodology
could support the decision-making process about orphan medicines in the context of CatSalut.
Methods: The assessment and decision-making process for orphan drugs in the Programa d’Harmonització
Farmacoterapeutica (PHF) of CatSalut was prioritized to test the implementation of the reflective MCDA both a
qualitative and quantitatively. A staged approach was used with the following main steps: selection and
structuration of quantitative criteria (Core Model) and qualitative criteria (Contextual Tool), framework scoring and
assessment of three orphan drug case studies.
This proof-of-concept would grant a continued refinement of the methodology and, if and when validated, its
potential integration to other therapeutic areas of the PHF.
Results: The final framework was composed by 10 quantitative criteria (Core Model) and 4 qualitative criteria
(Contextual Tool) according to the PHF goals being the most important criteria “disease severity”, “unmet need”,
“comparative effectiveness” and “comparative safety /tolerability”. The matrix developed for the case studies served
as a guide for the selection of the essential information that the decision-makers were expected to include in a
framework. The reflective discussion was considered the most relevant phase of the approach to support inputs for
health decision-making processes reflecting both drug value and place in therapy.
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Conclusions: The study showed that reflective MCDA methodology could be implemented to complement the
decision-making process in CatSalut, as an aid to determine the clinical added value for orphan medicines. MCDA
provided transparency and a structured discussion during the committee meetings, thus increasing transparency
and predictability of the relevant items supporting the agreements adopted on orphan drugs access.
Keywords: Multi-criteria decision analysis, Catalan healthcare, Orphan drugs, Decision-making
Introduction
In Spain, the decision for price and reimbursement of
therapeutic innovations in the basic services portfolio of
the public health care system is a national responsibility.
However, the other health competences are mainly
dependent on the autonomous communities who are
responsible for the budget allowance, prioritization and
development of measures to ensure efficient access of
new drugs considering the characteristics of their own
population [1].
In Catalonia, the Catalan Health Care System (Servei
Català de la Salut, CatSalut) is the regional health care
institution responsible for ensuring public access and
rights for health delivery. CatSalut runs a specific
program for drug evaluation and decision-making,
Programa d’Harmonització Farmacoterapeutica (PHF)
aimed to prioritize innovative drugs according to their
added value and considering the needs and budgeting
priorities, while to guaranteeing equity in the access to
treatments throughout Catalonia. In addition to establish
the relative effectiveness, PHF also specifies the clinical
criteria recommendations and the place in therapy of
the new drug in relation to available therapies [2]. A
dedicated committee composed by 18 members (6
physicians, 6 healthcare service managers, 5 pharmacists
and 1 patient representative) was specifically devoted to
decision-making regarding of Orphan Drugs at the time
of the present exercise.
To address the PHF goals, CatSalut began an initiative
in 2015 focused on a multidimensional assessment of
drugs value [3]. Among all the multicriteria approaches,
the reflective multicriteria decision analysis (MCDA)
was chosen since, through analytical methods, helps to
contextualize all the relevant data related with the
product and which could contribute to a decision [4].
Reflective MCDA framework (EVIDEM) is composed by
a set of criteria derived from the ethical imperatives of
healthcare and their relative importance under a trans-
parent and standardised process which promote the
reflection of the stakeholders and facilitate the sharing
of diverse perspectives [5, 6].
The first step was focused on adapting and assessing
the value of a decision reflective MCDA framework for
orphan drugs evaluation from CatSalut perspective. The
standard evaluation and decision-making procedure of
CatSalut was compared with the reflective MCDA meth-
odology and was adapted to the local context. Finally, it
was concluded that reflective MCDA could be a useful
and feasible tool to complement the current evaluation
methods of CatSalut, contributing to standardisation
and pragmatism, providing a method to tackle ethical
dilemmas and facilitating discussions related to decision-
making [7]. This initiative was included in the Health
Plan of Catalonia for 2016–2020 [2].
Thus, the aim of the present study was to assess the
feasibility of the implementation of a reflective MCDA
methodology to support orphan drug decision-making
process to the Catalan context.
Methods
A qualitative study was carried out with a staged ap-
proach. The following main steps were used: 1) selection
and structuration of quantitative criteria (MCDA core
Model) and qualitative criteria (Contextual Tool), 2)
weighting of the quantitative criteria of the framework
and 3) testing through assessment of three orphan drug
case studies.
Selection and structuration of criteria for orphan drugs
framework
An updated specific MCDA framework for orphan
medicines evaluation was developed considering the
suggested quantitative and qualitative criteria of the pilot
framework previously developed (December 2015), [7] and
additional criteria identified through the following sources:
– Updated version of EVIDEM framework (v.4): New
considerations of the EVIDEM framework which is
continually updated by the EVIDEM collaboration
group to support pragmatic and reflective healthcare
decision-making [8]
– Systematic Literature Review (SLR): Criteria from a
SLR conducted by the Instituto Carlos III (ISCIII).
The study identifies and analyses the information
about the reimbursement criteria and
pharmaceutical policies used for orphan drugs
decision-making applied in the main countries of the
European Union, Australia and Canada. Their search
strategy covered literature published between to
2004 and 2015 [3].
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The abovementioned resources were analysed in order
to assess the feasibility of their adaptation for the inclu-
sion in the current PHF. The analysis was performed by
two of the authors (XB and LG).
The final version of the framework was discussed and
validated indicating whether a criterion should or should
not be systematically considered when appraising a
orphan drug in the setting of the PHF by 5 members of
PHF (physicians, pharmacists and health service man-
agers). Definition of criteria is similar to EVIDEM
framework focused on orphan drugs [8].
Weighting of orphan drugs framework (value system
elicitation)
The weighting of the quantitative criteria of the final
orphan drugs framework was done by a subgroup of
representatives of the committee of CatSalut in charge
of decision-making processes (clinicians and hospital
pharmacist during a workshop performed on July 2017
in Barcelona). This subgroup was selected to enable the
properly field testing of the orphan drug framework and
was trained on reflective MCDA methodology previously
to participate in the panel.
A direct rating scale (five-point weighting technique)
was used where each participant gave a relative weight
per criterion using a nonhierarchical simple 5-point
scale (1 = lowest relative importance, 5 = highest relative
importance) [8, 9].
Data analysis
All data analysis was carried out in Microsoft Excel.
Criteria weights were normalized to sum up to 1 for
each participant: for the 5-point rating scale method,
each weight was divided by the sum of weights across all
criteria; for the point allocation method, criteria ratings
were multiplied by domain weight and rescaled to range
from 0 to 1 [8].
Case studies – appraisal of three orphan drugs
Three orphan drugs approved in Europe were chosen to
test the suitability of the proposed MCDA framework to
capture all the relevant dimensions and criteria used for
discussion. The medicines selected were chosen from
medicines already scheduled for assessment by the PHF,
and considering the fact that the 3 drugs differed in
terms of size of target population, availability of treat-
ment alternatives, quantity and quality of the supporting
evidence and economical impact, among others, The
available evidence was summarized for each orphan drug
in the evidence matrix, following the reflective MCDA
methodology [8].
During the workshop performed on July 2017, the par-
ticipating PHF members rated individually the three
orphan drugs matrix for each drug assessment, consider-
ing the Catalan healthcare context.
Data analysis
Data were collected individually, transferred to a
common database and analysed with Microsoft Excel. A
descriptive analysis of the value of each criterion was
conducted separately. Non-comparative criteria were
rated in a 0 (worst) to 5 (best) scale and comparative cri-
teria (efficacy, safety, PRO (Patient Reported Outcomes)
and cost) was rated in a scale from − 5 to 5. For each
criterion, the mean, standard deviation (SD) and range
of minimum and maximum scores were calculated. The
value contribution (Vx) of each quantitative criterion
was then calculated as the product of its normalised
scoring (Wx, ∑ Wx = 1) and standardised score (non
comparative criteria: Sx = score/5 or comparative criteria:
Sx = score/10). The overall MCDA value estimate (V) of
each orphan drugs was calculated based on a linear
additive model as a sum the value contributions (Vx) of
all (n) criteria of the quantitative criteria [8, 10]:
VE ¼
Xn
x¼1
VCx ¼
Xn
x¼1
Wx  Sxð Þ
Results
Selection and structuration of the criteria for orphan
drugs framework
The pilot framework developed in the previous study [7]
considers a set of criteria structured into two distinct
sections: MCDA Core Model, composed of 13 quantita-
tive criteria selected for the assessment of the drug and
a MCDA Contextual tool, composed of 4 qualitative
criteria that consider the context surrounding decision-
making (Table 1).
In addition, seven new criteria were analysed by the
PHF members in order to decide their introduction or
modification in the updated version of the framework
(Table 2).
All the criteria from Table 2 were accounted to assess
if they could complement the orphan drugs framework.
Some considerations were provided by PHF members
regarding the goals and content of the program:
– Size of affected population: The ethical basis of this
criterion reflects an aspect of the utilitarianism
principle (greatest good for greatest number).
Orphan drugs target small populations. Then, this
principle, albeit important, need to be considered as
a low priority, in order to minimise differences
between rare and ultra-rare diseases. It was agreed
to exclude the criteria.
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– Preventive benefit: the vast majority of rare diseases
are of genetic origin and interventions are therefore
symptomatic or curative rather than preventive. It
was concerted to exclude the criteria.
– Therapeutic benefit: Based on its definition, the
nature of the clinical benefit provided for patient-
level intervention (i.e, symptom relief, prolongation
of the life, healing), the criterion was maintained in
the framework. However, it will be redefined so that it
captures the therapeutic benefit in a broad and far-
reaching way, including aspects such as reduction of
risk factors, reduction in disease transmission, etc.
– Non-medical costs: Although non-medical expenses
are highly relevant to rare diseases, the lack of infor-
mation and the difficulty to quantify them makes
them difficult to consider. It was agreed to exclude
the criteria.
– Budget Impact: Relevant criteria for drug assessment
in PHF process. It was agreed to include the criteria
to the domain “feasibility contextual criteria”
(Contextual tool). Furthermore, its inclusion
supports the exclusion of the criteria “size of the
population”, which would be covered with the
financial/budgeting exercise.
– Rarity: The concept of common disease, rare or
ultra -rare, is closely related with the number of
patients affected. To be consistent with the
exclusion of “size of affected population” criteria it
was agreed not to include this criterion.
– The rule of rescue: The criterion describes the
perceived duty to save endangered life whenever
possible although the drug is not indicated or
cost-effective. It was agreed to exclude the
criteria.
Table 1 Criteria considered in the pilot framework
Criteria Type of criteria Source
Disease severity Quantitative Previous study [7]
Size of affected population Quantitative Previous study [7]
Unmet needs Quantitative Previous study [7]
Comparative effectiveness Quantitative Previous study [7]
Comparative safety/tolerability Quantitative Previous study [7]
Comparative patients perceived health (PRO) Quantitative Previous study [7]
Type of preventive benefit Quantitative Previous study [7]
Type of therapeutic benefit Quantitative Previous study [7]
Cost of orphan drug Quantitative Previous study [7]
Other medical costs Quantitative Previous study [7]
Non-medical costs Quantitative Previous study [7]
Quality of evidence Quantitative Previous study [7]
Expert consensus / clinical practice guidelines Quantitative Previous study [7]
Population priorities and access Qualitative Previous study [7]
Common goal and specific interests Qualitative Previous study [7]
Opportunity costs and affordability Qualitative Previous study [7]
System capacity and appropriate use of intervention Qualitative Previous study [7]
PRO Patient Reported Outcomes
Table 2 Additional criteria considered for orphan drugs framework
Criteria Type of criteria (quantitative/qualitative) Source
Size of affected population Quantitative Previous study [7]
Preventive benefit Quantitative Previous study [7]
Therapeutic benefit Quantitative Previous study [7]
Non-medical costs Quantitative Previous study [7]
Budget Impact Quantitative or qualitative EVIDEM framework v.4 [8] and SLR [3]
Rarity Quantitative or qualitative SLR [3]
The rule of rescue Quantitative or qualitative SLR [3]
SLR Systematic Literature Review
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The final orphan drugs framework validated by partici-
pants is shown as Table 3.
Weighting of orphan drugs framework (value system
elicitation)
According to the results collected from the 5-point
weighting scale (Fig. 1), the more important criteria for
orphan drugs were “disease severity and unmet needs”
(4,7 points ± 0,5) followed by “comparative effectiveness”
(4,6 points ± 0,5) and “comparative safety/ tolerability”
(4,4 points ± 0,7). The least important criteria were “ex-
pert consensus /clinical practise guidelines” (2,4 points ±
0,7) and “quality of evidence” (2,8 points ± 1,2).
Case studies – appraisal of 3 orphan drugs
The next step involved in the implementation approach
of the framework in the drug review process was
appraising three orphan drugs: alpha 1-antitrypsin for
alpha1-antitrypsin deficiency, eliglustat for Gaucher
disease and tolvaptan for autosomal dominant polycystic
kidney disease.
The matrix developed for the case studies served as a
guide for the relevant information that decision-makers
expect to include in a framework.
The overall scores achieved for each orphan drug,
including the contribution of the individual criteria
scores to the total are depicted in Figs. 2, 3, 4 and 5.
– Disease severity of the alpha – 1 antitrypsin
deficiency was considered high, reflecting the
perception of their impact on mortality and
morbidity. Alpha – 1 antitrypsin was not considered
to have an added value versus standard of care in
regards to efficacy, safety and quality of life
(QoL). Regarding the type of benefit, alpha – 1
antitrypsin was considered as not providing an
added therapeutic benefit, considering
improvements on clinical variables or imaging
abnormalities. Comparative treatment cost and
other medical costs were assessed with a neutral
score. Related to its inclusion in the international
guidelines and quality of evidence for alpha – 1
antitrypsin was considered moderate, because of
uncertainty in the methodology and results of the
clinical trial publication.
– Gaucher disease was considered a very severe
disease reflecting a high estimated mortality and
co-morbidities because of impairment of relevant
organs such as liver, spleen, bone marrow and
bones. Some enzyme replacement therapies have
been approved for Gaucher disease: imiglucerase,
velaglucerase and miglustat. Eliglustat is an oral
treatment that was considered similar to the
previously approved drugs in regards to the
therapeutic efficacy, but with the advantage of oral
route despite a worst safety profile, although
possibly better than the other oral alternative
miglustat. The QoL outcomes were seen as
translating this fact in a benefit for the patients.
Treatment cost per patient and other medical costs
Table 3 MCDA Core Model (criteria appraised quantitatively) and MCDA Contextual Tool (criteria appraised qualitatively)
MCDA Core Model
Domains Criteria
Disease Impact Disease severity
Unmet needs
Comparative outcomes of orphan drugs Improvement of efficacy/effectiveness
Improvement of safety/ tolerability
Improvement of patient perceived health/PRO
Type of therapeutic benefit
Economic consequences of intervention Annual patient cost of treatment
Other medical costs
Knowledge about intervention Quality of evidence
Expert consensus/clinical practice guidelines
MCDA Contextual Tool
Domains Criteria
Normative contextual criteria Population priorities and access (principle of equity)
Common goal and specific interests
Feasibility contextual criteria System capacity and appropriate use of orphan drugs
Opportunity costs and affordability (budget impact)
MCDA Multiple Criteria Decision Analysis
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were assessed with slightly positive score to
eliglustat. Quality of evidence was considered low.
Eliglustat was not included in the spansish
recommendation about Gaucher disease [11]
management since by the time of the guideline
publication eliglustat was not yet approved by the
European Medicines Agency (EMA).
– Autosomal dominant polycystic kidney disease was
perceived as a very severe disease with an
unfavourable prognostic based on reduced survival
of these patients, and the lack of effective
alternatives. It was observed that the efficacy of
tolvaptan was moderately better than placebo
although it is accompanied with a worst safety
profile. There was no published data related to QoL,
for this reason the score was considered neutral.
Regarding the type of benefit tolvaptan was judged
to provide a moderate therapeutic benefit.
Comparative treatment cost was assessed with a
negative score to tolvaptan and other medical costs
with neutral score given the lack of available
evidence related to these criteria. Quality of
evidence was considered very low due to the poor
external validity or applicability. The ERA-EDTA
(European Renal Association and European Dialysis
and Transplant Association) recommended tolvap-
tan with some clinical criteria of use.
The overall MCDA value estimates (V) of each orphan
drug were 0.16, 0.23 and 0.22, for alpha-1 antitrypsin,
eliglustat and tolvaptan, respectively. The utility of the
overall MCDA value estimates was discussed, and the
PHF members considered that MCDA contributed
most to decision making process when criteria were
described separately, rather than described through a
summary score. The PHF members considered that a
structured approach to multiple criteria allowed
focusing discussion into most relevant domains and
criteria, avoided potential linking between numeric
thresholds and decisions, and thus added most value
from the multidimensional approach to their process
of decision-making.
Discussion
The outcome of this study provides valuable insight on
the implementation of the multicriteria orphan drug
Fig. 1 Mean (SD) of level of importance rated by participants to final
orphan drugs framework. SD: standard deviation; PRO: Patient
Reported Outcomes
Fig. 2 Comparison of value contribution of each criterion: alpha – 1
antitrypsin, tolvaptan and eliglustat. PRO: Patient Reported Outcomes
Fig. 3 Value of contribution of each criteria: alpha – 1 antitrypsin vs
BSC. PRO: Patient Reported Outcomes
Fig. 4 Value of contribution of each criteria: eliglustat vs imiglucerase.
PRO: Patient Reported Outcomes
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assessment in the CatSalut context. MCDA would be
feasible to support the assessment of reflective value of
new orphan drugs, and may be useful to structure and
conduct a deliberate the discussion during the PHF
committee meetings.
Evaluation and decision-making for orphan drugs is a
challenge, due to the inherent difficulties to generate a
high-quality evidence of value in small populations. For
this reason, the management of orphan drugs often
implies areas of substantial uncertainty. Such scenario
was suitable for testing whether the reflective multicri-
teria tool might be able to provide perspective and facili-
tating decision-making through a systematic, consistent
and integrated approach to several dimensions of assess-
ment. MCDA allows visualizing the criteria that may be
not explicitly informed during the decisions reached in
medicines evaluation committees meetings, such as
unmet needs, severity of the disease and QoL, as well as
other contextual variables which could contribute to
reach a final decision considering the complexity of the
drug, the potentially treated population and/or the
complexity of its environment.
Reflective MCDA can be used to quantify the import-
ance of the different criteria of assessment and the
relevance assigned to specific items. Furthermore, it was
regarded that quantitative modelling had to be sup-
ported by a qualitative descriptive approach, similar to a
process of consensus. Reflective MCDA allowed to iden-
tify the range of results for the dimensions and for each
assessment criteria, as well as the relevance assigned to
specific results. Theses ranges and results were used to
prepare qualitative discussion in a structured qualitative
approach that is designed to support the identification
and communication of the most relevant criteria.
MCDA in this case would not be used as a formula to
come to a decision, but rather as a tool to complement
the values and viewpoints of committee members,
allowing visualization and traceability of key decision
elements and making them transparent and supportive
of the reflection during discussion across the range of
dimensions in the overall assessment of a new drug,
ensuring a systematic and thorough procedure. The ap-
proach helps to focus the discussion, providing a
common structure which is similar across products. Also
allows to identify points with diverging opinions from
the multidisciplinary decision-making committee.
Another strength of MCDA is that it is suited to in-
corporate the interpretation of the evidence from differ-
ent perspectives (reasoning the scoring and weights
value), and the methodology has the advantage of
providing sufficient flexibility to incorporate relevant
items tailored to singular cases and/or situations that
may be incorporated rapidly to PHF process within the
established framework. Although the MCDA was
adapted to the process of the PHF, the adaption is
tailored to our process, and may be non-generalizable to
other purposes or contexts. However, similar processes
can be made to adapt MCDA in other settings.
There have been attempts in Europe to implement
reflective MCDA approaches to support managed
deliberation through considerations, avoiding the way
predominant group members can take over decision-
making [12].
Friedmann et al. [12], reviewed the existing evidence
regarding the use of MCDA in the assessment of orphan
drugs worldwide. A total of seven articles suggest that
MCDA is increasingly being used in the context orphan
drug assessment. MCDA demonstrate to be a flexible as-
sessment with the potential to assisting decision-making
regarding reimbursement for orphan drugs [12]. The
main findings of the 7 articles reviewed by Friedmann et
al. report the use of the EVIDEM framework in several
studies, with criteria concerning disease-specific, health
intervention-specific and contextual factors. In our study
“disease severity” and “clinical efficacy/effectiveness”
were considered the most relevant criteria for the assess-
ment of orphan drugs, similarly than reported by other
institutions [12]. Additionally, our results considered the
criterion “unmet clinical need” as very relevant. In con-
trast, in previously published studies “Other comparative
costs” and “treatment innovation” were the criteria con-
sidered as less important [12], while in our exercise the
less relevant criteria were “quality of evidence” and “expert
consensus/clinical practise guidelines”.
In Italy, the Lombardy health directorate has used a
reflective multicriteria approach combined with the
European network for health technology assessment
(EUnetHTA) core model to appraise health technologies
and make health funding coverage decisions since 2012.
The interaction with stakeholders was facilitated by a
transparent process and demonstration of reasonable-
ness. The process was evolving to further increase
Fig. 5 Value of contribution of each criteria: tolvaptan vs placebo.
PRO: Patient Reported Outcomes
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legitimacy by involving a wider array of stakeholders
such as citizens or patients [4, 13].
The implementation of a reflective MCDA method-
ology to support orphan drug decision-making follows
one of the nine recommendations set up by the
European Working Group for Value Assessment and
Fundings Processes in Rare Diseases (ORPH-VAL),
which propose that orphan drug assessment should
consider all relevant elements of product value in an
appropriate multi-dimensional framework [14].
The current study has some limitations. The constitu-
tion of only a subgroup representative of committee to
enable the properly test of the tool could imply that not
all the different perspectives were taken into account
during the discussion (health economists, bioethical and
patient representatives didn’t participate in the study).
Another limitation of the study was that the scenario
adopted just focused on orphan drug assessment, which
for their particular challenges, led to exclusion of some
criteria relevant for common diseases. The scope of
CatSalut committee is to take decisions on both rare
and common diseases showing that the framework needs
to be expanded from orphan drugs to non-orphan drugs
medicine products.
Additionally, another limitation was the description of
the concept and definitions of each criterion which
could have been more explicit to reduce the variability
of the interpretation by the decision-makers. Such
variability might have conditioned different results for
the scoring and weighting phases.
Finally, it is important to highlight that the synthesis
of the evidence to develop the evidence matrix could
minimise the advantages of the tool, which are focused
on the identification of the variety of points of views and
promotion of a multidimensional reflective discussion.
Conclusion
This study shows that MCDA methodology could be-
come a systematic procedure to complement the overall
process of assessment of the added clinical value of
innovative medicines by CatSalut.
There is a growing understanding that the assessment
based only on traditional criteria such as clinical efficacy,
safety and cost, does not allow the value of a new drug to
be fully captured. Considering the goal to promote the
quality of drug prescription, MCDA allows a deep explor-
ation of a set of quantitative and qualitative inputs, includ-
ing reflective discussions and individual comments
facilitating the evaluation of innovative drug, positioning
medicines within therapeutic algorithms and allowing
equitable resource allocation in the healthcare sector.
By integration of MCDA to the PHF procedures,
MCDA could support the technical evaluation report
providing a structured, standardised and transparent
approach, contextualising the relevant data for each drug
and facilitating evidence and ethical-based discussions
among all the different stakeholders involved in evalu-
ation and decision-making purposes.
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